University Gastroenterology (UGI), a leading provider of digestive health care in Rhode Island and Southeastern Massachusetts, has launched a series of clinical trials studying the use of GLP-1 medications for patients with fatty liver disease (MASH), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).
The statistics are staggering. African Americans are 20% more likely to get colon cancer and 40% more likely to die from the disease than any other racial group. That is why University Gastroenterology – Southern New England’s largest gastroenterology practice – is launching a campaign coinciding with Black History Month aimed at informing the Black community about the symptoms, the risks, and the importance of knowing your family history.
The more than 25 years of experience Jonathan Friedman has in healthcare administration will allow the doctors at UGI to focus on what’s most important – patient care.
info@practicemarcomm.com